# EDGAR Filing Document

**Accession Number:** 0000921114
**File Stem:** 0001104659-26-039180
**Filing Date:** 2026-4
**Character Count:** 5711
**Document Hash:** 136366c25418c9182f0eaf70fde0a656
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-26-039180.hdr.sgml**: 20260402

**ACCESSION NUMBER**: 0001104659-26-039180

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 11

**CONFORMED PERIOD OF REPORT**: 20260402

**ITEM INFORMATION**: Other Events

**FILED AS OF DATE**: 20260402

**DATE AS OF CHANGE**: 20260402

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Armata Pharmaceuticals, Inc.
- **CENTRAL INDEX KEY:** 0000921114
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 911549568
- **STATE OF INCORPORATION:** WA
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37544
- **FILM NUMBER:** 26833778

**BUSINESS ADDRESS:**
- **STREET 1:** 5005 MCCONNELL AVE
- **CITY:** LOS ANGELES
- **STATE:** CA
- **ZIP:** 90066
- **BUSINESS PHONE:** 310-665-2928

**MAIL ADDRESS:**
- **STREET 1:** 5005 MCCONNELL AVE
- **CITY:** LOS ANGELES
- **STATE:** CA
- **ZIP:** 90066

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** AmpliPhi Biosciences Corp
- **DATE OF NAME CHANGE:** 20130222

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** TARGETED GENETICS CORP /WA/
- **DATE OF NAME CHANGE:** 19940331

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, DC 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of report (Date of earliest event reported): **April 2, 2026**

**ARMATA PHARMACEUTICALS, INC.**

(Exact name of Registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Washington** | **001-37544** | **91-1549568** |
| (State or other jurisdiction <br> of incorporation or organization) | (Commission File Number) | (IRS Employer Identification No.) |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;**5005 McConnell Avenue**<br> **Los Angeles, California** | &nbsp;&nbsp; **90066** |
| &nbsp;&nbsp;(Address of principal executive offices) | &nbsp;&nbsp;(Zip Code) |

---

**(310) 655-2928**

(Registrant's Telephone number)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions (see General Instruction A.2. below):

◻ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

◻ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

◻ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

◻ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ◻

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of Each Class | Trading Symbol(s) | Name of Each Exchange on Which Registered |
| **Common Stock** | **ARMP** | **NYSE American** |

---

---

| | |
|:---|:---|
| **Item 8.01** | **Other Events.** |

---

Armata Pharmaceuticals, Inc. ("Armata" or the "Company") has set June 11, 2026 as the date for its 2026 annual meeting of stockholders (the "Annual Meeting"). The Annual Meeting will be held at 8:30 a.m. (Pacific Time), at the Company's principal executive offices at 5005 McConnell Avenue, Los Angeles, California 90066, or at such other time and location to be determined by the Company's Board of Directors and set forth in the Company's proxy statement for the Annual Meeting. Armata's stockholders of record at the close of business on April 17, 2026, will be entitled to notice of the Annual Meeting and to vote upon matters considered at the Annual Meeting.

The deadline for receipt of stockholder proposals and director nominations submitted pursuant to Section 2.6 of Armata's Amended and Restated Bylaws for consideration at the Annual Meeting is 5:00 p.m. (Pacific Time) on April 12, 2026 (the "Advance Notice Bylaws Provision Deadline"). Stockholder proposals and director nominations should be submitted in writing and must be received by the Corporate Secretary at Armata's principal executive offices at Armata Pharmaceuticals, Inc., 5005 McConnell Avenue, Los Angeles, California 90066, by the Advance Notice Bylaws Provision Deadline, in order to be considered timely. Stockholder proposals and nominations submitted pursuant to Armata's advance notice bylaw provisions must also comply with the advance notice provisions contained in Armata's Amended and Restated Bylaws and may be omitted if not in compliance with applicable requirements. Stockholders are urged to read the complete text of such advance notice provisions.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| Date: April 2, 2026 | **Armata Pharmaceuticals, Inc.** | **Armata Pharmaceuticals, Inc.** |
|  | By: | /s/ David House |
|  | Name: | David House |
|  | Title: | Senior Vice President, Finance and Principal Financial Officer |

---